Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Exploring the Impact of AI on Human Resource Management: A Case Study of Organizational Adaptation and Employee Dynamics Abstract: This study investigates the transformative impact of artificial ...

Kyle Harrison, the 23-year-old lefty who the Red Sox acquired from the Giants in the Rafael Devers trade, struggled in his organizational debut Thursday.

When the Trump Organization announced its cellular brand earlier this month, it touted that the devices would be “made in the USA,” keeping in line with Trump administration policies.

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was challenged over a potential conflict of interest.

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on ...

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, ...

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive ...

The latest update was submitted on June 24, 2025, indicating ongoing recruitment and progress. For investors, this study represents a significant development in Regeneron’s cardiovascular portfolio.

Marietta Wealth Management raised its stake in Regeneron Pharmaceuticals by 30.2% in the first quarter, now holding 10,778 shares valued at $6.8 million. Several other institutional investors also ...